Popular weight-loss drugs tied to unexpected nail condition

KUALA LUMPUR, 13 OCTOBER 2026 —

Popular GLP‑1 weight‑loss drugs have been linked to a markedly higher incidence of nail detachment, hair loss and scalp inflammation, a multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 showed.

The study examined 575 adults who were currently using a GLP‑1 medication and compared them with 1,329 control participants who had type‑2 diabetes and/or obesity but had never taken a GLP‑1 drug. Participants were recruited from France, the United States, Brazil and Mexico. Overall, 66 % of GLP‑1 users reported at least one nail disorder, versus 53 % of the control group.

Nail detachment – the separation of the nail from the underlying skin – was reported by 39 % of users, more than four times the 9 % reported by non‑users. Nail discoloration affected 46 % of users compared with 17 % of controls.

The researchers asked whether rapid weight loss, a known trigger of hair and nail changes, could explain the differences. Even when the analysis was limited to participants who had lost weight, GLP‑1 users continued to report significantly more nail problems than non‑users. “Until now, nail changes associated with GLP‑1 therapies had essentially been anecdotal,” said study author Dr Charles Taïeb.

“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP‑1 treatment is necessarily caused by the treatment itself.”

Half of the GLP‑1 cohort reported unusual hair loss, compared with 34 % of the control group. Reduced hair volume or density was noted by 42 % of users versus 19 % of non‑users. Hair loss that began after treatment initiation was reported by 26 % of GLP‑1 users, more than double the 12 % reported by controls. Scalp redness was approximately three times more frequent among users.

Most participants who experienced shedding also reported accompanying scalp symptoms such as itching, redness or flaking, suggesting an inflammatory component. “Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable,” explained co‑author Dr Bruno Halioua.

The study also examined pre‑existing conditions. Approximately half of the medication users said they had experienced nail problems before starting GLP‑1 therapy. After adjusting for existing skin disorders and nutritional deficiencies, the differences in nail detachment and discoloration narrowed but remained roughly two to three times higher among GLP‑1 users than among controls.

Researchers emphasized that the observations do not prove causation. Both investigations were cross‑sectional, relying on participants’ self‑reported symptoms rather than standardized clinical examinations, and therefore cannot establish a temporal relationship between drug exposure and dermatological changes. “These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,” said Dr Halioua.

“Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy.”

The team plans prospective studies that will follow patients from the start of GLP‑1 treatment, incorporate standardized skin, hair and nail examinations and include biological monitoring. The aim is to pinpoint when the changes first appear, uncover underlying mechanisms and determine whether the symptoms resolve or persist over time.

The research received institutional support from DUCRAY Laboratories, a subsidiary of the Pierre Fabre Group that develops dermatological and hair‑care products. Materials were provided by Beyond, with the original Science Daily release dated 12 October 2026.

Related: European Academy of Dermatology and Venereology (EADV) Congress 2026